Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to pinpoint how Genpact recognizes contract revenue or which segment drives its digital transformation growth? With subsidiaries across 25+ countries, Genpact’s disclosures can stretch beyond 250 pages, and the footnotes on long-term service contracts, Data-Tech-AI investments, and client concentration often hide deep inside. If you’re searching for “Genpact SEC filings explained simply,” this page delivers. Stock Titan surfaces the answers in seconds.
Our AI-powered summaries translate every Genpact SEC document—from an 8-K on a new outsourcing deal to the annual report 10-K—into plain language. Whether you search “Genpact insider trading Form 4 transactions” or “understanding Genpact SEC documents with AI,” you’ll find real-time insights, keyword tagging, and cross-linking that make navigation effortless.
Need the latest numbers? The “Genpact quarterly earnings report 10-Q filing” section highlights revenue by vertical, margin movement, and cash-flow trends, while our dashboards compare quarter-over-quarter performance. For governance questions, the proxy statement area breaks down Genpact executive compensation, option awards, and CEO pay ratio. Monitoring management moves? Get instant alerts on “Genpact Form 4 insider transactions real-time” so you never miss a buyback or stock grant.
Every filing type is covered and explained:
- 10-K annual report—strategy shifts, customer concentration, risk factors simplified (“Genpact annual report 10-K simplified”).
- 10-Q quarterly update—data tables annotated, segment commentary summarized (“Genpact earnings report filing analysis”).
- 8-K material events—contract wins or leadership changes distilled (“Genpact 8-K material events explained”).
- Form 4—executive stock moves tracked live (“Genpact executive stock transactions Form 4”).
- DEF 14A proxy—board structure and incentive plans clarified (“Genpact proxy statement executive compensation”).
Stop scrolling through PDFs. Stock Titan delivers real-time filing updates, context-rich charts, and expert analysis tailored to Genpact’s business-process management model—so you can focus on decisions, not document hunting.
Genpact Limited reported an insider equity award to its President and CEO, who is also a director. On December 17, 2025, the executive received 125,130 restricted share units (RSUs) of Genpact common shares at a price of $0 per share, granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Each RSU converts into one common share when it vests.
One-third of the shares underlying this RSU award will vest on each of December 17, 2026, December 17, 2027 and December 17, 2028, contingent on the executive’s continued service through each vesting date. After this transaction, the executive beneficially owns 420,376 Genpact common shares directly.
Genpact LTD disclosed an insider ownership report for one of its senior executives. The filing relates to Sydney Schaub, who serves as SVP and Chief Legal Officer, with an event date of 12/08/2025.
According to the filing, no Genpact securities are beneficially owned, as noted in the explanation of responses. The form is filed for a single reporting person and is signed by Thomas D. Scholtes as attorney-in-fact for Sydney Schaub under a referenced power of attorney (Exhibit 24.1).
Genpact Limited announced that its subsidiaries Genpact UK Finco plc and Genpact USA, Inc. completed a public Notes Offering of
Genpact intends to use the net proceeds for general corporate purposes, which may include repaying or redeeming its existing 1.750% senior notes due
Genpact Ltd (G) reported that its Chief Financial Officer filed a Form 4 disclosing an open-market sale of company stock. On 11/14/2025, the CFO sold 13,365 common shares of Genpact at a weighted average price of $44.84 per share, with individual sale prices ranging from $44.81 to $44.89. Following this transaction, the reporting person beneficially owns 148,026 Genpact common shares. This total includes 1,358 shares held under the Genpact Employee Stock Purchase Plan, of which 169 shares were acquired under the plan since a prior report filed on March 13, 2025.
Genpact UK Finco plc and Genpact USA, Inc. priced a $350,000,000 offering of 4.950% Senior Notes due 2030, fully and unconditionally guaranteed on a senior unsecured basis by Genpact Limited and Genpact Luxembourg S.à r.l. The notes mature on November 18, 2030 and pay interest semi-annually on May 18 and November 18, starting May 18, 2026.
The notes were offered at 99.593% with a 0.400% underwriting discount, resulting in proceeds before expenses of $347,175,500; Genpact estimates net proceeds of approximately $345.4 million. The company intends to use the net proceeds for general corporate purposes, which may include repaying or redeeming the 1.750% Senior Notes due 2026, of which approximately $350 million is outstanding, at or prior to their April 10, 2026 maturity.
The notes are senior unsecured obligations with optional redemption at a make‑whole premium before October 18, 2030 and at par thereafter, and include a change of control repurchase at 101% of principal. Genpact plans to apply to list the notes on The International Stock Exchange; there is currently no public market.
Form 144 filing: A holder notified intent to sell up to 13,365 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 11/14/2025. The filing lists an aggregate market value of $599,314.67 for the planned sale.
The shares were acquired as restricted stock from the issuer on 08/02/2022. As context, 172,414,423 shares were outstanding at the time referenced.
Genpact (G) reported insider transactions by its SVP & Chief Legal Officer. On 11/11/2025, the officer sold 1,039 common shares at $44.02. On 11/12/2025 and 11/13/2025, the officer exercised employee stock options at $27.7 for 4,351 and 45,703 shares, respectively, and sold the corresponding shares at $45.74. Following these transactions, the officer directly beneficially owned 50,569 common shares. The reported option grant was scheduled to expire on 01/09/2029 and vested 50% on January 10, 2022 and 50% on January 10, 2024.
Genpact Ltd (G) — Form 4 insider transaction: Senior Vice President Sameer Dewan reported a sale of 26,531 common shares on 11/11/2025, coded “S” for sale. The weighted average price was $44.7, with disclosed trade prices ranging from $44.70 to $44.7305.
Following the transaction, Dewan beneficially owns 62,617 shares, held directly.
Genpact Ltd (G) director Tamara Franklin reported a sale of 2,750 common shares at $45.65 on November 12, 2025, according to a Form 4 filing. Following the transaction, she beneficially owns 22,236 shares, held directly. The filing lists a transaction code “S,” indicating a sale, and shows no derivative securities activity reported.
G: A selling holder filed a Form 144 notice to sell 45,703 shares of common stock with an aggregate market value of $2,090,455.22, through Morgan Stanley Smith Barney LLC, with an approximate sale date of 11/13/2025 on the NYSE.
The shares were acquired via a stock option exercise on 11/13/2025 for cash. In the past three months, HEATHER D WHITE reported sales of 4,351 shares for $199,014.74 on 11/12/2025 and 1,039 shares for $45,731.59 on 11/11/2025. Shares outstanding were 172,414,423.
FAQ
What is the current stock price of Genpact (G)?
What is the market cap of Genpact (G)?
